BRPI0601285A8 - uso de agomelatina na obtenção de medicamentos destinados ao tratamento de distúrbios bipolares - Google Patents

uso de agomelatina na obtenção de medicamentos destinados ao tratamento de distúrbios bipolares

Info

Publication number
BRPI0601285A8
BRPI0601285A8 BRPI0601285A BRPI0601285A BRPI0601285A8 BR PI0601285 A8 BRPI0601285 A8 BR PI0601285A8 BR PI0601285 A BRPI0601285 A BR PI0601285A BR PI0601285 A BRPI0601285 A BR PI0601285A BR PI0601285 A8 BRPI0601285 A8 BR PI0601285A8
Authority
BR
Brazil
Prior art keywords
bipolar disorders
agomelatine
treatment
obtaining drugs
obtaining
Prior art date
Application number
BRPI0601285A
Other languages
English (en)
Inventor
De Bodinat Christian
Mocaer Elisabeth
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35311309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0601285(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of BRPI0601285A publication Critical patent/BRPI0601285A/pt
Publication of BRPI0601285A8 publication Critical patent/BRPI0601285A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

uso de agomelatina na obtenção de medicamentos destinados ao tratamento de distúrbios bipolares. a presente invenção refere-se ao uso de agomelatina, ou n-[2-(7-metóxi-1-naftil)etil]acetamida, por si só, ou em associação, na obtenção de medicamentos destinados ao tratamento de distúrbios bipolares, especialmente distúrbios bipolares dos tipos i e ii, e mais especialmente distúrbios bipolares do tipo i.
BRPI0601285A 2005-04-20 2006-04-20 uso de agomelatina na obtenção de medicamentos destinados ao tratamento de distúrbios bipolares BRPI0601285A8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0503937A FR2884714B1 (fr) 2005-04-20 2005-04-20 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires

Publications (2)

Publication Number Publication Date
BRPI0601285A BRPI0601285A (pt) 2006-12-19
BRPI0601285A8 true BRPI0601285A8 (pt) 2021-03-30

Family

ID=35311309

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0601285A BRPI0601285A8 (pt) 2005-04-20 2006-04-20 uso de agomelatina na obtenção de medicamentos destinados ao tratamento de distúrbios bipolares

Country Status (41)

Country Link
US (1) US7947743B2 (pt)
EP (1) EP1714647B1 (pt)
JP (2) JP4580364B2 (pt)
KR (2) KR100835451B1 (pt)
CN (2) CN102038669A (pt)
AP (1) AP2656A (pt)
AR (1) AR057277A1 (pt)
AT (1) ATE491443T1 (pt)
AU (1) AU2006201655B2 (pt)
BR (1) BRPI0601285A8 (pt)
CA (1) CA2544136C (pt)
CR (1) CR9426A (pt)
CY (1) CY1111257T1 (pt)
DE (1) DE602006018822D1 (pt)
DK (1) DK1714647T3 (pt)
EA (1) EA013462B1 (pt)
ES (1) ES2357901T3 (pt)
FR (1) FR2884714B1 (pt)
GE (1) GEP20094651B (pt)
GT (1) GT200600141A (pt)
HK (1) HK1093906A1 (pt)
HR (1) HRP20110083T1 (pt)
IL (1) IL186373A (pt)
JO (1) JO2666B1 (pt)
MA (1) MA28266A1 (pt)
ME (1) ME01951B (pt)
MY (1) MY143171A (pt)
NO (1) NO336010B1 (pt)
NZ (1) NZ546630A (pt)
PE (1) PE20061337A1 (pt)
PL (1) PL1714647T3 (pt)
PT (1) PT1714647E (pt)
RS (1) RS51659B (pt)
SG (1) SG126868A1 (pt)
SI (1) SI1714647T1 (pt)
TN (1) TNSN07364A1 (pt)
TW (2) TW200940049A (pt)
UA (1) UA83681C2 (pt)
UY (1) UY29470A1 (pt)
WO (1) WO2006111653A1 (pt)
ZA (1) ZA200603160B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890563B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent
AU2008247805A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl) acetamides
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2856934A1 (en) * 2013-10-04 2015-04-08 Les Laboratoires Servier Biomarkers for the prediction of long term remission in depression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5585118A (en) * 1995-06-02 1996-12-17 Brigham And Women's Hospital Choline in the treatment of bipolar disorder
RS50680B (sr) * 2001-02-27 2010-06-30 Ortho-Mcneil Pharmaceutical Inc. Karbamatna jedinjenja za upotrebu u sprečavanju i lečenju bipolarnih poremećaja
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
JP2007517040A (ja) * 2003-12-24 2007-06-28 セプレイコー インコーポレイテッド 睡眠の質を改善するためのメラトニン併用療法

Also Published As

Publication number Publication date
HRP20110083T1 (hr) 2011-03-31
EP1714647B1 (fr) 2010-12-15
HK1093906A1 (en) 2007-03-16
JO2666B1 (en) 2012-06-17
US20060240127A1 (en) 2006-10-26
UA83681C2 (uk) 2008-08-11
AU2006201655B2 (en) 2009-04-23
ES2357901T3 (es) 2011-05-03
CR9426A (es) 2008-02-21
IL186373A0 (en) 2008-08-07
GT200600141A (es) 2006-11-22
EA200600600A1 (ru) 2006-10-27
BRPI0601285A (pt) 2006-12-19
KR100835451B1 (ko) 2008-06-09
GEP20094651B (en) 2009-03-25
JP2010280699A (ja) 2010-12-16
CA2544136C (fr) 2012-02-21
MY143171A (en) 2011-03-31
ATE491443T1 (de) 2011-01-15
JP4580364B2 (ja) 2010-11-10
JP5341037B2 (ja) 2013-11-13
SI1714647T1 (sl) 2011-03-31
TW200940049A (en) 2009-10-01
EP1714647A1 (fr) 2006-10-25
RS51659B (en) 2011-10-31
ME01951B (me) 2011-10-31
SG126868A1 (en) 2006-11-29
PT1714647E (pt) 2011-01-14
NO336010B1 (no) 2015-04-20
CN1853619B (zh) 2011-02-02
US7947743B2 (en) 2011-05-24
JP2006316056A (ja) 2006-11-24
PL1714647T3 (pl) 2011-05-31
TW200716083A (en) 2007-05-01
MA28266A1 (fr) 2006-11-01
NZ546630A (en) 2007-09-28
ZA200603160B (en) 2007-06-27
CA2544136A1 (fr) 2006-10-20
AU2006201655A1 (en) 2006-11-09
AR057277A1 (es) 2007-11-28
TWI318115B (en) 2009-12-11
CN102038669A (zh) 2011-05-04
FR2884714A1 (fr) 2006-10-27
TNSN07364A1 (en) 2008-12-31
CN1853619A (zh) 2006-11-01
AP2007004212A0 (en) 2007-10-31
KR20080028389A (ko) 2008-03-31
NO20061705L (no) 2006-10-23
DK1714647T3 (da) 2011-03-07
AP2656A (en) 2013-05-07
DE602006018822D1 (de) 2011-01-27
KR20060110803A (ko) 2006-10-25
WO2006111653A1 (fr) 2006-10-26
CY1111257T1 (el) 2015-08-05
UY29470A1 (es) 2006-05-31
FR2884714B1 (fr) 2011-05-06
EA013462B1 (ru) 2010-04-30
IL186373A (en) 2012-06-28
PE20061337A1 (es) 2007-01-27

Similar Documents

Publication Publication Date Title
EA200601449A1 (ru) Применение агомелатина для получения лекарственных средств, предназначенных для лечения нарушений сна у пациента с депрессией
JO3440B1 (ar) استخدام الأغوميلاتين في تحضير علاجات لمداولة اضطرابات القلق العام.
BRPI0601285A8 (pt) uso de agomelatina na obtenção de medicamentos destinados ao tratamento de distúrbios bipolares
JO2656B1 (en) Use of agomelatine to obtain medications for the treatment of Smith Magnes syndrome
EA201201123A1 (ru) Применение агомелатина для получения лекарственных средств, предназначенных для лечения обсессивно-компульсивного расстройства (окр)
JO2631B1 (en) Use agomelatine to obtain medications to treat leukoplakia around the brain ventricles
CU20070232A7 (es) Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento de los trastornos bipolares
EA200601450A1 (ru) Новая комбинация агомелатина и тиморегулирующего средства и фармацевтические композиции, которые её содержат

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: C07C 233/18 (2006.01), A61P 25/18 (2006.01), A61P

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B03H Publication of an application: rectification [chapter 3.8 patent gazette]

Free format text: REFERENTE A RPI 1876 DE 19/12/2006, QUANTO AO ITEM (32).

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2622 DE 06-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.